Brian Gorman, Clinical Trials Controversy, Fool.com, June 21, 2004. Gorman points out some of the negatives to open access to clinical trials. Concerns facing companies might include arming their competitors, that "phase 1 and phase 2 trials may or may not be accurate indicators of a medicine's effect on a larger population," and the difficulty of interpreting results in general. "Purists may argue that more openness is always a good idea. But in this case, releasing more of this data may increase, rather than relieve, confusion."
Posted by
Garrett at 6/24/2004 04:30:00 PM.
The open access movement:
Putting peer-reviewed scientific and scholarly literature
on the internet. Making it available free of charge and
free of most copyright and licensing restrictions.
Removing the barriers to serious research.
I recommend the OA tracking project (OATP) as the best way to stay on top of new OA developments. You can read the OATP feed on a blog-like web page or subscribe to it by RSS, email, or Twitter. You can also help build the feed by tagging new developments you encounter.
